Huabei pharmaceutical: amoxicillin capsule, metformin hydrochloride tablets have passed the consistency evaluation!

On January 15, Huabei pharmaceutical released a notice that metformin hydrochloride tablets (0.5g) and Amoxicillin Capsules (0.5g, 0.25g) of the company passed the consistency evaluation Amoxicillin amoxicillin belongs to penicillin broad spectrum β - lactam antibiotics have strong antibacterial and bactericidal effects on most of the pathogenic Gram-positive and Gram-negative bacteria They are widely used in the treatment of upper respiratory tract infection caused by sensitive bacteria, urogenital tract infection, skin and soft tissue infection, lower respiratory tract infection and other drugs to eradicate Helicobacter pylori, and there is no need to adjust the dosage in patients with mild to moderate nephropathy Since the implementation of the consistency evaluation, the cumulative R & D investment for the two specifications of the drug is 10.3876 million yuan (Unaudited) At present, there are 239 approval documents for amoxicillin capsule production in China The company is the third domestic enterprise that has passed the consistency evaluation of amoxicillin capsule (0.5g) and the tenth enterprise that has passed the consistency evaluation of amoxicillin capsule (0.25g) According to the announcement, the company's sales revenue of the product in 2018 was 137678100 yuan At present, amoxicillin capsule sales enterprises are analyzed as follows: metformin hydrochloride tablets metformin hydrochloride tablets are the first choice for simple diet control and physical exercise to control blood glucose ineffective type 2 diabetes For adults, it can be used in single drug therapy or combined with sulfonylurea or insulin For children and adolescents aged 10 and over, it can be used for single drug therapy or combined therapy with insulin This product was developed by Merck and listed in France in 1957 under the trade name of Glucophage It was approved to be listed in the United States by FDA on March 3, 1995 Since the implementation of the consistency evaluation, about 8.28 million yuan (Unaudited) has been invested in the research and development of the drug At present, there are eight metformin hydrochloride tablets (0.5g) in China, and the company is the second enterprise that has passed the consistency evaluation of the product (0.5g) The sales revenue of the company's product in 2018 is 457000 yuan According to the pharmaceutical intelligence data hospital sales database, the market share is still occupied by the original research manufacturers Mengmeng's article is the integrated content of yaozhi.com, and the copyright belongs to the original author The purpose of reprint is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.